Access to Innovative Treatments Act of 2026

This bill requires the Centers for Medicare & Medicaid Services (CMS) to review adverse national coverage determinations of drugs under Medicare within 30 days of receiving a request to do so.

Read the full summary in the Pocket Congress app.